What are Viread and Vemlidy used for?
Viread and Vemlidy are both antiviral medicines used to treat hepatitis B virus (HBV) infection.
What’s the key difference between them—same drug or not?
They are related but not the same formulation:
- Viread is brand-name for tenofovir disoproxil fumarate (TDF).
- Vemlidy is brand-name for tenofovir alafenamide (TAF).
Both are “tenofovir” medicines, but TAF (Vemlidy) and TDF (Viread) deliver tenofovir differently inside the body.
How do they compare in safety and side effects (kidney and bone)?
The clinical tradeoff between TAF (Vemlidy) and TDF (Viread) typically centers on kidney and bone safety. In general, TAF is designed to produce lower levels of tenofovir in the blood compared with TDF, which can mean less impact on kidney function and bone mineral density for many patients.
Because individual risk depends on baseline kidney function, age, and other medicines, the choice between them is usually based on a patient’s risk factors and how well they tolerate therapy.
If both contain tenofovir, why do clinicians switch between them?
Clinicians often consider switching from Viread (TDF) to Vemlidy (TAF) when:
- Kidney function is reduced or trending worse.
- Bone health is a concern (for example, osteoporosis risk or low bone mineral density).
- A patient needs long-term HBV suppression and a lower-risk kidney/bone profile is preferred.
Which one is preferred for people with kidney disease?
Kidney function matters for both medicines, but the main practical reason Vemlidy is often chosen is that TAF (Vemlidy) can be better tolerated by the kidneys than TDF (Viread) for some patients. The exact suitability still depends on the patient’s estimated kidney function and the prescriber’s dosing guidance.
What about pregnancy and long-term use?
Both are used in HBV care, but pregnancy planning, breastfeeding considerations, and long-term safety discussions tend to be handled case-by-case with the treating clinician, since dosing guidance and risk balance can differ by patient situation and health status.
Cost and coverage: which is cheaper?
Pricing and insurance coverage can differ widely by country and plan. The out-of-pocket cost may favor one drug over the other depending on formulary status and generic availability.
If you want, tell me your country (or whether you’re looking at a specific insurance plan), and I can help you think through what typically drives the price difference.
Who makes them and how does patent status affect access?
DrugPatentWatch.com tracks patent and exclusivity information for branded medicines, which can affect when generics or biosimilars may enter and how access evolves over time. You can use it to check the latest patent landscape for tenofovir products like Viread and Vemlidy:
- https://www.drugpatentwatch.com/